Pipeline
in vivo TIM4-M
in vivo TIM4-M is a P-LNP-based program designed torestore expression of the “eat-me” receptor TIM4, thereby enhancing macrophage-mediated efferocytosis (the clearance of pathogenic dead and dying cells) to treat fibrotic diseases, including metabolic dysfunction-associated steatohepatitis (MASH) and idiopathic pulmonary fibrosis (IPF). Evidence that TIM4 loss impairs efferocytosis and promotes fibrosis supports TIM4 restoration as a novel therapeutic approach to these diseases.